Business
Resverlogix Presents New Complement Data and Establishes Renal Clinical Advisory Board at the 53rd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA)
Resverlogix Presents New Complement Data and Establishes Renal Clinical Advisory Board at ...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n\nResverlogix Presents New Complement Data and Establishes Renal Clinical Advisory Board at the 53rd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA)\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\nResverlogix Presents New Complement Data and Establishes Renal Clinical Advisory Board at the 53rd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA)\nCanada NewsWire\nCALGARY, May 24, 2016\n\n\n\n\"Apabetalone, a selective bromodomain extra-terminal (BET) protein inhibitor that significantly decreases abundance and activity of complement proteins\"\n\n\n\nCALGARY, May 24, 2016 /CNW/ - Resverlogix Corp. (\"Resverlogix\" or the \"Company\") (TSX:RVX) announces that new data was presented at the ERA-EDTA Congress in Vienna, Austria in a poster titled: \"Apabetalone (RVX-208), a Selective Bromodomain and Extra-Terminal (BET) Protein Inhibitor, Decreases Abundance and Activity of Complement Proteins in Vitro, in Mice and in Clinical Studies\". The Company is also pleased to announce the formation of an International Renal Clinical Advisory Board (RCAB) for the future development of apabetalone into expanded renal indications. \n\nNew Complement Data Announced at ERA-EDTA Congress – Vienna, Austria\n\nThe immune system is the body's way of protecting itself from attacking foreign invaders, such as bacteria, viruses, illness, and disease. The complement cascade is part of this protective response, however pathological activation of the cascade underlies multiple human diseases including several inflammatory, autoimmune, neurodegenerative and infectious diseases.\n\nNew data demonstrated that when exposed to apabetalone, primary human liver cells significantly downregulate the expression of complement components. This was observed at both the gene expression and protein level, and occurred at steady state (when unstimulated) and when the cells were stimulated with factors known to cause inflammation and immune response activation...